Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 25Carcinoma, Non-Small-Cell Lung 14Squamous Cell Carcinoma of Head and Neck 11Melanoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Colorectal Neoplasms 9Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Liver Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Neoplasm Metastasis 3Mesothelioma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × tremelimumab × Clear all
NCT03539822 2026-01-21

CAMILLA

University of Pittsburgh

Phase 1/2 Recruiting
117 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT04817826 2025-06-10

INFINITY

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting
31 enrolled
Gastrointestinal

Stomach Neoplasms, Microsatellite Instability

NCT03959293 2024-07-08

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Federation Francophone de Cancerologie Digestive

Phase 2 Active not recruiting
107 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Asan Medical Center

Phase 1/2 Completed
58 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡